RANI THERAPEUTICS HOLDINGS-A

RANINASDAQ

🏆 #4455 by market capUS Equity

$613.81▼ $15.77 (−2.57%)

Simulated price

🔔

Track RANI

Get earnings, price moves & breaking news on Telegram

Track

24h▼ 2.6%

7d—

14d—

30d—

ytd—

1y—

🏦Market Cap

$51M

Small Cap

📈Revenue Growth (YoY)

+58.9%

High Growth

📊Gross Margin

96.7%

High

💵FCF Margin

-417.0%

Thin

⚖️P/S Ratio

10.4x

Elevated

Otter Score

Good

No chart data available for RANI.

Trading Snapshot

Day Range: $611.26 – $624.48
52-Week Range: $0.39 – $3.87
Volume: $3.05B
Avg Volume: $2.15B
Shares Outstanding: 65.3M
Next Earnings: Nov 1, 2026

Fundamentals Snapshot

Annual Revenue: $5M
Last Q Revenue: $1M
P/E Ratio: -2.9
P/S Ratio: 10.4x
EPS (TTM): $-0.16
Dividend Yield: 0.00%

Why Investors Own RANI

✓High-growth profile — revenue up +58.1% YoY with expanding US Equity exposure.
✓Healthy economics — 63% gross margin and 21% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

RANI THERAPEUTICS HOLDINGS-A

RANI

Financial Trends

Revenue (TTM)

$5M▲ +52.0% YoY

Gross Margin (TTM)

63.2%▼ −0.1% YoY

Operating Income (TTM)

$892,491▲ +52.0% YoY

Free Cash Flow (TTM)

$1M▲ +52.0% YoY

StockOtter · stockotter.space

About RANI THERAPEUTICS HOLDINGS-A

Rani Therapeutics Holdings, Inc. functions as a clinical-stage biopharmaceutical enterprise focused on revolutionizing the delivery of biologic therapies through oral administration. Its flagship innovation, the RaniPill capsule, aims to supplant conventional subcutaneous or intravenous injections of biologics with a more convenient oral dosing method. The company maintains a comprehensive portfolio of investigational treatments. Among these is RT-101, an octreotide, which has progressed beyond Phase I clinical trials for the management of neuroendocrine tumors and acromegaly. Another promising candidate is RT-105, an anti-TNF-alpha antibody designed to address psoriatic arthritis. Additionally, RT-102, a parathyroid hormone for osteoporosis, is currently advancing through preclinical studies. Other therapies under development include RT-109, a human growth hormone for treating growth hormone deficiency; RT-110, a parathyroid hormone aimed at hypoparathyroidism; and RT-106, a basal insulin formulated for type 2 diabetes. Established in 2012, the company's corporate base is located in San Jose, California.

🦦